Skip to content
10-K

Annual Report

Compass Therapeutics, Inc. CMPX

0001171843-25-001106

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 15, 2025 138.28M sh
Capex FY 2024 · Dec 31, 2023 $30K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$40.62M
Cash And Equivalents FY 2024 · Dec 31, 2023 $24.23M
Current Liabilities FY 2024 · Dec 31, 2023 $7.8M
Total Liabilities FY 2024 · Dec 31, 2023 $8.34M
Current Assets FY 2024 · Dec 31, 2023 $153.88M
Total Assets FY 2024 · Dec 31, 2023 $156.88M
Eps Basic FY 2024 · Dec 31, 2023 −$0.33
Sga Expense FY 2024 · Dec 31, 2023 $12.24M
Rd Expense FY 2024 · Dec 31, 2023 $38.12M
Net Income FY 2024 · Dec 31, 2023 −$42.49M
Operating Income FY 2024 · Dec 31, 2023 −$50.36M
Revenue FY 2024 · Dec 31, 2023 $0
Stockholders Equity FY 2024 · Dec 31, 2022 $181.64M